Abstract
BackgroundABO blood type is an established prognostic factor in several malignancies, but its role in esophageal cancer (EC) is largely unknown. The aim of this study is to determine whether ABO blood group is associated with survival after esophagectomy for EC.MethodsA total of 406 patients who underwent surgery for EC were enrolled. The associations of ABO blood group with clinical and pathological variables were assessed using chi-square test. Associations of ABO blood group with the survival were estimated using univariable and multivariable Cox proportional hazards regression models.ResultsThe ABO blood group proportionally associated with the grade of EC tumor (P = 0.049). The ABO blood group status did not correlate with disease-free survival (DFS) in univariable analysis or multivariable analysis (P > 0.05). And there was no significant relationship between the ABO blood group and overall survival (OS) in univariable analysis or multivariable analysis (P > 0.05).ConclusionsOur results suggested that no association between ABO blood group and the survival was observed in patients undergoing surgery for EC.Electronic supplementary materialThe online version of this article (doi:10.1186/s12893-015-0094-1) contains supplementary material, which is available to authorized users.
Highlights
ABO blood type is an established prognostic factor in several malignancies, but its role in esophageal cancer (EC) is largely unknown
Patient selection During the period of patient enrollment, among of 429 cases with symptom, 397 cases were diagnosed as EC, and among of 647 cases without symptom, 24 cases were diagnosed as EC
No significant difference was observed between ABO blood groups and disease-free survival (DFS) rate for the EC patients (P = 0.121)
Summary
ABO blood type is an established prognostic factor in several malignancies, but its role in esophageal cancer (EC) is largely unknown. The aim of this study is to determine whether ABO blood group is associated with survival after esophagectomy for EC. Esophageal cancer (EC) was ranked as the eighth most common cancer worldwide, with 482,300 new cases estimated in 2008, and the sixth most common cause of death from cancer with 406,800 deaths [1]. Surgery is still the mainstay of treatment for patients with EC. One of the reasons is that many cases are at the advanced stage on diagnosis. It is well known that cancer can be caused by the interaction between environmental factors and genetic variations. Several risk factors related to EC have been
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
